Imagine visiting your doctor’s office. Instead of swiping a copay card and filling out a paper form by hand, the receptionist says, “We take Apple Health.” You wave your iPhone over a digital kiosk, instantly uploading your current medical record and insurance information. Your copay is then deducted from a health savings account. Voila! The doctor will see you now. This scenario is no longer relegated to the distant future.
Read More
Pharma
3 Reasons to Implement an IDMP Solution Early
The European Union (EU) has announced guidance on the Identification of Medicinal Product (IDMP) — and pharmaceutical companies around the world should take notice. While the EU will be the first to design and implement IDMP, other countries, including the United States, will need to begin following suit. It’s imperative that companies begin evaluating what changes need to be implemented, and the sooner pharmaceutical companies act, the better. Designed to connect data elements and
Read More
The Gains and Pains of Using AI in the Pharmaceutical Industry
The costs for drug discovery and development are skyrocketing, but AI (artificial intelligence) is introducing new efficiencies to help find effective treatments faster. A study in 2020 concluded that the estimated median capitalized research and development cost per product was $985 million. Contributing factors to this included larger trial sizes, the need to assess health technology, the requirement to provide data on comparative drugs’ effectiveness, and most
Read More
ObvioHealth & Oracle Collaborate to Seamlessly Integrate Diverse Data Sets Into Decentralized Clinical Trials in APAC
What You Should Know: - Today, ObvioHealth and Oracle have announced a partnership to enable the rapid collection, integration and analysis of this complex data to get breakthrough therapies to market faster and cheaper within the APAC region. This partnership will integrate ObvioGo, ObvioHealth’s next generation decentralized clinical trial (DCT) platform and mobile app, and Oracle Clinical One Cloud Service, facilitating pharma-grade analytics and reporting that can
Read More
ChristianaCare Spins Out New Gene Editing Company, CorriXR Therapeutics
What You Should Know: - ChristianaCare recently announced it has spun out its first commercial biotechnology private startup company, named CorriXR Therapeutics. The company will use CRISPR gene editing technology to develop new, clinically relevant oncologic therapeutics in areas of unmet medical need, starting with squamous cell carcinoma of the lung. Its close relationship with ChristianaCare and the ChristianaCare Gene Editing Institute uniquely positions it to research and develop
Read More
State Price Transparency Requirements Are No Longer Cut and Paste
For pharmaceutical manufacturing firms, the amount of documentation required around state price transparency regulations continues to expand. As it now stands, more than 22 states have transparency laws on the books, and each of these states requires a complicated and diverse set of reporting information, which was not the case five years ago. These transparency requirements – including the need to provide data in different formats and on different dates due to “triggering events” – mean that
Read More
Qnovia Secures $17M to Advance Inhalable Therapeutics Pipeline
What You Should Know: - Qnovia (formerly Respira Technologies)—a pharma company developing inhaled therapeutics with an initial focus on nicotine replacement therapy (NRT) and cardiopulmonary diseases—has raised $17M in Series A funding led by Blue Ledge Capital and included DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures. - Qnovia will use the Series A proceeds to advance its NRT drug candidate through an IND submission with the FDA and begin human
Read More
Digiceuticals: Driving Growth Through Digital Health Services
There was tremendous interest in telemedicine before 2020. However, the COVID-19 pandemic made it a reality triggering unprecedented disruption across the industry. For instance, digital-first healthcare aggregators had been testing programs for telemedicine but, since 2020, the demand for telehealth services has exploded across the globe. Despite stabilizing forces such as vaccine rollouts, telehealth utilization remains 38 times higher than it was in the years before the pandemic (1). Health
Read More
It’s Time to Give Patients “Admin Access” to Manage Their Healthcare
While the entire healthcare industry is inching toward giving people more autonomy to manage their care, we can’t seem to hand over the keys just yet. The latest KLAS data on patient preferences shows that most individuals interacting with the healthcare system want greater control, especially over their care visits. That’s because the capabilities patients value most—including appointment scheduling, prescription refill
Read More
Lyfegen Raises $8M for Value-Based Contracting for High-Cost Drugs
What You Should Know: - Lyfegen, a global health tech SaaS company driving the world’s transition from volume to value-based healthcare for high-cost drugs raises $8M in Series A financing round led by aMoon, with additional participation from APEX Ventures and others. - Lyfegen’s value-based contracting software is used by healthcare payers and leading pharma companies, including Novartis, Roche, MSD, Bristol Myers Squibb (BMS) and Johnson & Johnson. Value-Based
Read More
